{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "6312877",
  "DateCompleted": {
    "Year": "1983",
    "Month": "11",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "05",
    "Day": "05"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0166-3542",
      "JournalIssue": {
        "Volume": "3",
        "Issue": "2",
        "PubDate": {
          "Year": "1983",
          "Month": "Aug"
        }
      },
      "Title": "Antiviral research",
      "ISOAbbreviation": "Antiviral Res"
    },
    "ArticleTitle": "An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2.",
    "Pagination": {
      "StartPage": "121",
      "EndPage": "136",
      "MedlinePgn": "121-36"
    },
    "Abstract": {
      "AbstractText": [
        "Before the prophylactic effect of human interferon alpha 2 (HuIFN-alpha 2) can be tested against naturally acquired rhinovirus infection in a large-scale field trial, it is desirable to show that self-administration of the drug is practical, and to determine the smallest well-tolerated dose likely to produce a worthwhile effect. Here we report that self-administered intranasal interferon can be effective, and show how prophylaxis against rhinovirus infection is affected by both the quantity of interferon, and the interval between a dose and virus challenge. Finally, the medication regimen suggested for use in field trials (3.85 MU 3 times/day) was tested in a double-blind, placebo-controlled trial in volunteers. Although virus challenge was at a time when those being treated with interferon would be most susceptible, a substantial protective effect was still demonstrated."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Phillpotts",
        "ForeName": "R J",
        "Initials": "RJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Scott",
        "ForeName": "G M",
        "Initials": "GM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Higgins",
        "ForeName": "P G",
        "Initials": "PG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wallace",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Tyrrell",
        "ForeName": "D A",
        "Initials": "DA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gauci",
        "ForeName": "C L",
        "Initials": "CL"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Antiviral Res",
    "NlmUniqueID": "8109699",
    "ISSNLinking": "0166-3542"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interferon Type I"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Intranasal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Evaluation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Interferon Type I"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Rhinovirus"
    }
  ]
}